| Bioactivity | Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities[1][2]. | ||||||||||||
| In Vivo | Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B cells[2]. | ||||||||||||
| Name | Cevidoplenib | ||||||||||||
| CAS | 1703788-21-9 | ||||||||||||
| Formula | C25H27N7O3 | ||||||||||||
| Molar Mass | 473.53 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 31, No. 4, 2017. [2]. cevidoplenib dimesylate. |
Cevidoplenib
CAS: 1703788-21-9 F: C25H27N7O3 W: 473.53
Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immu
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.